Kane Biotech (CVE:KNE) Sets New 1-Year Low – What’s Next?

by · The Cerbat Gem

Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) reached a new 52-week low on Tuesday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 89000 shares trading hands. The stock had previously closed at C$0.04.

Kane Biotech Stock Performance

The company has a current ratio of 0.80, a quick ratio of 0.39 and a debt-to-equity ratio of -331.42. The company has a market cap of C$4.99 million, a price-to-earnings ratio of -0.33 and a beta of 0.29. The stock has a 50 day moving average price of C$0.04 and a two-hundred day moving average price of C$0.04.

About Kane Biotech

(Get Free Report)

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.

Featured Articles